The Ameliorative Effect of Liraglutide (Saxenda® and Victoza®) Treatment on Overweight and Induced Diabetes Mellitus Type 2 in Male Rats.

Hafth, Hanadi A.; Alwan, Nawras A.; Al-Masoudi, Eman A.

doi:10.23975/bjvr.2025.166936.1261

	The Ameliorative Effect of Liraglutide (Saxenda® and Victoza®) Treatment on Overweight and Induced Diabetes Mellitus Type 2 in Male Rats.
Basrah Journal of Veterinary Research
Volume 24, Issue 4, December 2025, Pages 142-153 PDF (420.69 K)
Document Type: Research Paper
DOI: 10.23975/bjvr.2025.166936.1261
Authors
Hanadi A. Hafth^* ¹; Nawras A. Alwan²; Eman A. Al-Masoudi²
¹Al-kunooze University, College of Dentistry
²Department of Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, Basrah University, Basrah, Iraq
Abstract
Recent researches are increasingly focused on incretin-based therapies, which use the body's natural "incretin effect" to manage diabetes and overweight. The study's goal is to utilize the incretin-mimicking medications to leverage their efficiency. 42 male rats were allocated into 7 groups (6 rats per group); G1 (Control) received an IP injection of NS for 4 weeks. G 2 (HFD group) is categorized into 3 subgroups. The positive control group received daily injections of normal saline for 4 weeks. Victoza- and Saxenda-treated groups were administered a graduated Sc dose from 0.6 to 1.2 mg/kg daily for 4 weeks. G3-induced diabetes mellitus type 2 (IDM) is categorized into three categories: Positive control: received daily injections of NS (1 ml/kg) for 4 weeks. The Victoza- and Saxenda-treated groups received Sc injections of graduated doses from 0.6 to 1.2 mg/kg daily for 4 weeks. The results showed a significant increase in incretin hormone in the HFD and IDM Victoza groups compared to the HFD and IDM Saxenda groups, while the insulin hormone showed a considerable decrease in HFD and IDM Victoza groups compared to the same groups treated with Saxenda. HDL showed a considerable elevation in groups IDM and HFD treated with Victoza, more those treated with Saxenda. LDL levels were significantly lower in the IDM and HFD groups treated with Victoza compared to those treated with Saxenda. The study shows that these two medications work by acting as agonists at the GLP-1 receptor, which in turn increases insulin secretion and improves incretin signaling
Keywords
Liraglutide; Glucagon-Like-Polypeptide-1 (GLP-1); Glucose inhibitory peptide (GIP); Victoza®; and Saxenda®

Statistics Article View: 216 PDF Download: 113